A further analysis of clinical trial data for sipuleucel-T (Provenge) suggests that it may have delivered a greater overall survival benefit than previously described.
Anita T. Shaffer
Advertisement
Articles by Anita T. Shaffer
While oncology specialists await the latest research news from the upcoming ASCO annual meeting next month, so do legions of biopharma investors. Here's a look at companies presenting pivotol trial data at this year's conference.
Advertisement
Latest Updated Articles
Revised View Enhances Provenge OS DataApril 20th 2012
Investors Eye ASCO Abstracts for Potential WinnersMay 19th 2011
Advertisement
Advertisement
Trending on Medical Economics
1
AI system outperforms physicians on diagnostic accuracy in Microsoft study
2
Florida's dengue outbreak: What physicians need to know now
3
Your AI scribe is saving you time. Is it also building the case against you?
4
Pay cuts, payer AI and the staff who keep leaving: What we heard at MGMA's 100th annual conference
5